Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
SCNI Scinai Immunotherapeutics	$1.82 +8.3%	$2.13	$1.40 ▼ $6.18	$1.82M	1.86	573,381 shs	1.50 million shs
SHPH Shuttle Pharmaceuticals	$3.50 -1.1%	$3.89	$3.00 ▼ $82.50	$1.54M	-1.08	131,041 shs	64,989 shs
TNFA TNF Pharmaceuticals	$0.10 -2.6%	$0.12	$0.08 ▼ $2.16	$1.45M	1.82	14.88 million shs	21.14 million shs
VIRX Viracta Therapeutics	$0.01	$0.01	$0.01 ▼ $0.56	$389K	1.06	1.11 million shs	N/A

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
SCNI Scinai Immunotherapeutics	+17.48%	+5.00%	-26.96%	-41.05%	-55.32%
SHPH Shuttle Pharmaceuticals	-1.39%	-1.67%	-10.15%	-36.27%	+353,999,900.00%
TNFA TNF Pharmaceuticals	-4.55%	+0.48%	+2.84%	-46.78%	+10,499,900.00%
VIRX Viracta Therapeutics	0.00%	0.00%	-3.17%	-44.11%	-97.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
SCNI Scinai Immunotherapeutics	1.2875 of 5 stars	0.0	2.0	0.0	0.0	3.8	2.5	0.6
SHPH Shuttle Pharmaceuticals	1.7785 of 5 stars	0.0	5.0	0.0	0.0	3.8	0.8	0.6
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIRX Viracta Therapeutics	1.6769 of 5 stars	3.2	3.0	0.0	0.0	0.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
SCNI Scinai Immunotherapeutics	0.00	N/A	N/A	N/A
SHPH Shuttle Pharmaceuticals	0.00	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	0.00	N/A	N/A	N/A
VIRX Viracta Therapeutics	2.33	Hold	$1.75	17,793.66% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
SCNI Scinai Immunotherapeutics	$660K	2.76	N/A	N/A	$5.10 per share	0.36
SHPH Shuttle Pharmaceuticals	N/A	N/A	N/A	N/A	$4.35 per share	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	$2.87 per share	N/A
VIRX Viracta Therapeutics	N/A	N/A	N/A	N/A	$0.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
SCNI Scinai Immunotherapeutics	$4.80M	-$9.57	N/A	∞	N/A	N/A	N/A	-40.60%	8/21/2025 (Estimated)
SHPH Shuttle Pharmaceuticals	-$9.15M	-$4.15	N/A	∞	N/A	N/A	-1,203.10%	-370.42%	9/2/2025 (Estimated)
TNFA TNF Pharmaceuticals	-$23.36M	-$6.67	N/A	∞	N/A	N/A	-97.38%	-37.37%	8/18/2025 (Estimated)
VIRX Viracta Therapeutics	-$51.06M	-$1.10	N/A	∞	N/A	N/A	-1,899.61%	-114.21%	N/A

Latest VIRX, SHPH, TNFA, and SCNI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	TNFA TNF Pharmaceuticals	N/A	-$0.36	N/A	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
SCNI Scinai Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
SHPH Shuttle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIRX Viracta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
SCNI Scinai Immunotherapeutics	0.06	1.32	1.32
SHPH Shuttle Pharmaceuticals	N/A	2.78	2.78
TNFA TNF Pharmaceuticals	N/A	1.37	1.37
VIRX Viracta Therapeutics	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
SCNI Scinai Immunotherapeutics	58.41%
SHPH Shuttle Pharmaceuticals	4.58%
TNFA TNF Pharmaceuticals	9.64%
VIRX Viracta Therapeutics	31.37%

Insider Ownership

Company	Insider Ownership
SCNI Scinai Immunotherapeutics	60.90%
SHPH Shuttle Pharmaceuticals	12.60%
TNFA TNF Pharmaceuticals	0.45%
VIRX Viracta Therapeutics	10.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
SCNI Scinai Immunotherapeutics	20	1.00 million	391,000	Not Optionable
SHPH Shuttle Pharmaceuticals	5	439,000	384,000	Not Optionable
TNFA TNF Pharmaceuticals	6	14.18 million	14.12 million	N/A
VIRX Viracta Therapeutics	20	39.74 million	35.50 million	No Data

VIRX, SHPH, TNFA, and SCNI Headlines

Recent News About These Companies

Calif. biotech company once worth $476M lays off every remaining employee

February 11, 2025 | msn.com

Viracta Therapeutics Terminates Employees & Winds Down Operations

February 8, 2025 | contractpharma.comC

Viracta Therapeutics, Inc.: Viracta Therapeutics Announces Wind Down of Operations

February 6, 2025 | finanznachrichten.de

Viracta Therapeutics Shuts Down Operations, Lays Off All Staff

February 6, 2025 | precisionmedicineonline.comP

Viracta Therapeutics terminates employees, to wind down operations

February 6, 2025 | markets.businessinsider.com

Viracta Therapeutics to cease operations and seek alternatives

February 5, 2025 | msn.com

Viracta Therapeutics Winds Down Operations, Terminates Employees

February 5, 2025 | marketwatch.com

Viracta Therapeutics hits end of the line, laying off all workers and winding down

February 5, 2025 | fiercebiotech.comF

Viracta Therapeutics, Inc. Announces Employee Terminations and Wind Down of Operations

February 5, 2025 | quiverquant.comQ

Viracta Therapeutics Announces Wind Down of Operations

February 5, 2025 | globenewswire.com

Why Did Viracta Therapeutics Inc (VIRX) Stock Tumble -46.67% to $0.08?

February 4, 2025 | bovnews.comB

VIRX stock plunges to 52-week low, touches $0.08

February 3, 2025 | msn.com

Viracta Therapeutics to be delisted from Nasdaq

February 3, 2025 | msn.com

Viracta Therapeutics strikes deal to avoid default

January 25, 2025 | msn.com

Viracta Therapeutics Inc (VIRX) Stock Trading Recap

January 10, 2025 | bovnews.comB

VIRX’s Unexpected Surge: What’s Next?

January 6, 2025 | bovnews.comB

Viracta Therapeutics Inc (VIRX) Stock Settles at $0.18: What’s Contributing to This Price Point?

January 3, 2025 | bovnews.comB

Cash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining options

January 3, 2025 | fiercebiotech.comF

Leerink Partners Issues Market Perform Rating for Viracta Therapeutics Inc (VIRX) Stock

December 30, 2024 | bovnews.comB

ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls

December 27, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRX, SHPH, TNFA, and SCNI Company Descriptions

Scinai Immunotherapeutics NASDAQ:SCNI

$1.82 +0.14 (+8.33%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 -0.02 (-1.10%)

As of 05:40 PM Eastern

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Shuttle Pharmaceuticals NASDAQ:SHPH

$3.50 -0.04 (-1.13%)

Closing price 04:00 PM Eastern

Extended Trading

$3.54 +0.04 (+1.14%)

As of 04:56 PM Eastern

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

TNF Pharmaceuticals NASDAQ:TNFA

$0.10 0.00 (-2.57%)

Closing price 04:00 PM Eastern

Extended Trading

$0.10 0.00 (-0.29%)

As of 05:43 PM Eastern

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Viracta Therapeutics NASDAQ:VIRX

$0.0098 0.00 (0.00%)

As of 07/25/2025

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time